Dermatology
enrollment form

Phone: 855-425-4085 **Fax:** 855-425-4096 **ardonhealth.com**

ardon

Date needed	Medication start date	Ship to: ☐ Patient ☐ Physician ☐ Other:

Patient information

Patient name	Date of birth		Phone	Alternate phone	
Address		City	State	ZIP	
Gender: ☐ Male ☐ Female	Email	Primary language		Height	Weight

Prescriber information

Prescriber name	State License #	NPI #	DEA #	
Group or hospital	Address	City	State	ZIP
Phone	Fax	Contact person name and phone		

Insurance information: If available, please fax a copy of the prescription and insurance card(s) with this form (front and back).

Clinical

Date of diagnosis	Diagnosis:
	☐ L40.0 Psoriasis Vulgaris ☐ L40.59 Psoriatic Arthritis ☐ L50.1 Idiopathic Urticaria ☐ New diagnosis ☐ L20.9 Atopic Dermatitis ☐ L73.2 Hidradenitis Suppurativa ☐ L28.1 Prurigo Nodularis ☐ Other _____

Prior therapies	Medication	Reason for discontinuation
☐ Biologics		
☐ Methotrexate		
☐ Oral Meds		
☐ PUVA		
☐ UVB		
☐ Topical		
☐ Other _____		

Current medications:

Is the patient also taking methotrexate? ☐ Yes ☐ No

Allergies:

Does the patient have a latex allergy? ☐ Yes ☐ No

Is the patient new to therapy? ☐ Yes ☐ No

BSA affected by _____%

Has patient had positive TB test? ☐ Yes ☐ No
If yes, date of last chest x-ray _____

Prescription information

Medication	Dose/strength	Directions	Quantity	Refill
☐ Bimzelx®	☐ 320 mg/2 mL Pen ☐ 320 mg/2 mL Prefilled Syringe ☐ 160 mg/mL Pen ☐ 160 mg/mL Prefilled Syringe	☐ Psoriasis Initiation Dose: Inject 320 mg SUBQ every 4 weeks at Weeks 0, 4, 8, 12 and 16	☐ 1 x 320 mg Pens/PFS ☐ 2 x 160 mg Pens/PFS	3
		☐ Psoriasis Maintenance Dose: Inject 320 mg SUBQ at week 16, then every 8 weeks thereafter	☐ 1 x 320 mg Pens/PFS ☐ 2 x 160 mg Pens/PFS	
		☐ Psoriasis (≥ 120 kg) Maintenance Dose: Inject 320 mg SUBQ at week 16, then every 4 weeks thereafter		
		☐ Hidradenitis Initiation Dose: Inject 320 mg SUBQ every 2 weeks at Weeks 0, 2, 4, 6, 8, 10, 12, 14 and 16	☐ 2 x 320 mg Pens/PFS ☐ 4 x 160 mg Pens/PFS	3
		☐ Hidradenitis Maintenance Dose: Inject 320 mg SUBQ at week 16, then every 4 weeks thereafter	☐ 1 x 320 mg Pens/PFS ☐ 2 x 160 mg Pens/PFS	

Physician signature required

Product substitution permitted	Dispense as written
X _____ Date _____	X _____ Date _____

Ancillary supplies and kits will be provided as needed for administration.

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document.

☐ Cibinqo®	☐ 50 mg Tablet ☐ 100 mg Tablet ☐ 200 mg Tablet	☐ Take 1 tablet by mouth once daily	☐ 30 Tablets	
☐ Cimzia®	**Starter Dose** ☐ Starter Kit (200 mg/mL Prefilled Syringes)	☐ Initiation Dose: Inject 400 mg SUBQ at weeks 0, 2, and 4	☐ 1 Kit = 6 x 200 mg/mL PFS	0
	Maintenance Dose ☐ 200 mg/mL Prefilled Syringe	☐ Psoriasis Maintenance Dose: Inject 400 mg SUBQ every 14 days	☐ 4 PFS	
		☐ Psoriasis Maintenance Dose (consideration if ≤ 90 kg): Inject 200 mg SUBQ every 14 days	☐ 2 PFS	
☐ Cosentyx®	☐ 300 mg/2 mL Pen	☐ Psoriasis and Hidradenitis Initiation Dose: Inject 300 mg SUBQ day 1, day 8, day 15, day 22, and then every 28 days starting on day 29	☐ 4 Pens	0
		☐ Psoriasis and Hidradenitis Maintenance Dose: Inject 300 mg SUBQ on day 29, then every 28 days thereafter	☐ 1 Pen	
		☐ Hidradenitis Maintenance Dose (if inadequate response): Inject 300 mg SUBQ every 14 days	☐ 2 Pens	
	☐ 150 mg/mL Pen ☐ 150 mg/mL Prefilled Syringe	☐ Psoriasis and Hidradenitis Initiation Dose: Inject 300 mg SUBQ day 1, day 8, day 15, day 22, and then every 28 days starting on day 29	☐ 8 Pens/PFS	0
		☐ Psoriasis and Hidradenitis Maintenance Dose: Inject 300 mg SUBQ on day 29 and then every 28 days thereafter	☐ 2 Pens/PFS	
		☐ Hidradenitis Maintenance Dose (if inadequate response): Inject 300 mg SUBQ every 14 days	☐ 4 Pens/PFS	
		☐ Psoriasis (pediatrics ≥ 50 kg) Initiation Dose: Inject 150 mg SUBQ day 1, day 8, day 15, day 22, and then every 28 days starting on day 29	☐ 4 Pens/PFS	0
		☐ Psoriasis (pediatrics ≥ 50 kg) Maintenance Dose: Inject 150 mg SUBQ on day 29, and then every 28 days thereafter	☐ 2 Pens/PFS	
	☐ 75 mg/0.5 mL Prefilled Syringe (pediatric)	☐ Psoriasis (pediatrics < 50 kg) Initiation Dose: Inject 75 mg SUBQ day 1, day 8, day 15, day 22, and then every 28 days starting on day 29	☐ 4 PFS	0
		☐ Psoriasis (pediatrics < 50 kg) Maintenance Dose: Inject 75 mg SUBQ on day 29, and then every 28 days thereafter	☐ 1 PFS	
☐ Dupixent®	☐ 300 mg/2 mL Pen ☐ 300 mg/2 mL Prefilled Syringe	☐ Atopic Dermatitis, Bullous Pemphigoid, Chronic Spontaneous Urticaria, and Prurigo Nodularis Initiation Dose: Inject 600 mg SUBQ on day 1, followed by 300 mg once every 14 days starting on day 15	☐ 4 Pens/PFS	0
		☐ Atopic Dermatitis, Bullous Pemphigoid, Chronic Spontaneous Urticaria, and Prurigo Nodularis Maintenance Dose: Inject 300 mg SUBQ every 14 days	☐ 2 Pens/PFS	
		☐ Atopic Dermatitis (pediatrics 6-17 years, 15 to < 30 kg) Initiation Dose: Inject 600 mg SUBQ on day 1, followed by 300 mg every 28 days starting on day 29	☐ 2 Pens/PFS	0
		☐ Atopic Dermatitis (pediatrics 6-17 years, 15 to < 30 kg) Maintenance Dose: Inject 300 mg SUBQ every 28 days	☐ 2 Pens/PFS	
		☐ Atopic Dermatitis (pediatrics 6 months-5 years, 15 to < 30 kg) Dose: Inject 300 mg SUBQ every 28 days		
	☐ 200 mg/1.14 mL Pen ☐ 200 mg/1.14 mL Prefilled Syringe	☐ Atopic Dermatitis (pediatrics 6-17 years, 30 to < 60 kg) and Chronic Spontaneous Urticaria (pediatrics 12-17 years, 30 to < 60 kg) Initiation Dose: Inject 400 mg SUBQ on day 1, followed by 200 mg every 14 days starting on day 15	☐ 4 Pens/PFS	0
		☐ Atopic Dermatitis (pediatrics 6-17 years, 30 to < 60 kg) and Chronic Spontaneous Urticaria (pediatrics 12-17 years, 30 to < 60 kg) Maintenance Dose: Inject 200 mg SUBQ every 14 days	☐ 2 Pens/PFS	
		☐ Atopic Dermatitis (pediatrics 6 months-5 years, 5 to < 15 kg) Dose (pediatric 6 months-5 years, 5 to <15 kg): Inject 200 mg SUBQ every 28 days	☐ 2 Pens/PFS	
☐ Ebglyss®	☐ 250 mg/2 mL Pen ☐ 250 mg/2 mL Prefilled Syringe	☐ Initiation Dose: Inject 500 mg SUBQ at week 0 and 2, followed by 250 mg every 2 weeks until week 16 or later	☐ 10 Pens/PFS	0
		☐ Maintenance Dose: Inject 250 mg SUBQ at week 16, then every 4 weeks thereafter	☐ 1 Pen/PFS	
☐ Enbrel®	☐ 50 mg/mL Pen ☐ 50 mg/mL Prefilled Syringe ☐ 50 mg/mL Mini Cartridge	☐ Psoriasis (adults) Initiation Dose: Inject 50 mg SUBQ 2 times weekly (3-4 days apart) for 3 months, then 50 mg every 7 days thereafter	☐ 8 Pens/PFS/ Cart	2
		☐ Psoriasis (adults and pediatrics ≥ 63 kg) Maintenance Dose: Inject 50 mg SUBQ every 7 days	☐ 4 Pens/PFS/ Cart	
	☐ 25 mg/0.5 mL Prefilled Syringe ☐ 25 mg/0.5 mL Single-dose Vial	☐ Psoriasis (pediatrics < 63 kg) Dose: Inject 0.8 mg/kg (dose = _____ mg) SUBQ every 7 days	4 PFS/Vials	
		☐ Other: _____		

Physician signature required

Product substitution permitted	**Dispense as written**
X _____ Date _____	X _____ Date _____

Ancillary supplies and kits will be provided as needed for administration.

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document.

☐ Humira®	**Starter Dose** ☐ 40 mg/0.8 mL Pen Psoriasis/ Adolescent Hidradenitis Starter (4 pens)	☐ Psoriasis and Adolescent Hidradenitis (30 to < 60 kg) Initiation Dose: Inject 80 mg SUBQ day 1, 40 mg day 8, then 40 mg every 14 days thereafter	☐ 1 Kit	0
	☐ 40 mg/0.8 mL Pen Hidradenitis Starter (6 pens)	☐ Hidradenitis Initiation Dose: Inject 160 mg SUBQ day 1, 80 mg day 15, then begin maintenance dose on day 29		
	Maintenance Dose ☐ 40 mg/0.8 mL Pen	☐ Inject 40 mg SUBQ every 14 days	☐ 2 Pens/PFS	
	☐ 40 mg/0.8 mL Prefilled Syringe	☐ Inject 40 mg SUBQ every 7 days	☐ 4 Pens/PFS	
☐ Humira® (Citrate-free)	**Starter Dose** ☐ 80 mg/0.8 mL and 40 mg/0.4 mL Pen Psoriasis/Adolescent Hidradenitis Starter (3 pens) ☐ 40 mg/0.4 mL Pen Psoriasis/ Adolescent Hidradenitis Starter (4 pens)	☐ Psoriasis and Adolescent Hidradenitis (30 to < 60 kg) Initiation Dose: Inject 80 mg SUBQ day 1, 40 mg day 8, then 40 mg every 14 days thereafter	☐ 1 Kit	0
	☐ 80 mg/0.8 mL Pen Hidradenitis Starter (3 pens)	☐ Hidradenitis Initiation Dose: Inject 160 mg SUBQ day 1, 80 mg day 15, then begin maintenance dose on day 29		
	Maintenance Dose ☐ 80 mg/0.8 mL CF Pen	☐ Inject 80 mg SUBQ every 14 days	☐ 2 Pens/PFS	
	☐ 40 mg/0.4 mL CF Pen	☐ Inject 40 mg SUBQ every 14 days	☐ 2 Pens/PFS	
	☐ 40 mg/0.4 mL CF Prefilled Syringe	☐ Inject 40 mg SUBQ every 7 days	☐ 4 Pens/PFS	
☐ Ilumya®	☐ 100 mg/mL Prefilled Syringe	☐ Initiation Dose: Inject 100 mg SUBQ at weeks 0 and 4, then every 12 weeks thereafter	☐ 1 PFS	0
		☐ Maintenance Dose: Inject 100 mg SUBQ at week 4, followed by every 12 weeks thereafter	☐ 1 PFS	
☐ Olumiant®	☐ 1 mg Tablet ☐ 2 mg Tablet ☐ 4 mg Tablet	☐ Take 1 tablet by mouth once daily	☐ 30 Tablets	
☐ Otezla®	☐ 75 mg XR Starter Pack ☐ 30 mg Starter Pack ☐ 20 mg Starter Pack (pediatrics 20 to < 50 kg)	☐ Initiation Dose: Take as directed per package instructions	☐ 1 Starter Kit	0
	☐ 75 mg XR Tablet ☐ 30 mg Tablet ☐ 20 mg Tablet (pediatrics 20 to < 50 kg)	☐ Maintenance Dose: Take 1 tablet by mouth once daily	☐ 30 Tablets	
		☐ Maintenance Dose: Take 1 tablet by mouth 2 times daily	☐ 60 Tablets	
		☐ Other: _____	_____ Tablets	
☐ Remicade®	☐ 100 mg vial	☐ Induction: Infuse _____ mg IV at weeks 0, 2, and 6	_____ Vial(s)	0
		☐ Maintenance: Infuse _____ mg IV every 8 weeks	_____ Vial(s)	
☐ Rinvoq®	☐ 15 mg XR Tablet	☐ Atopic Dermatitis Dose: Take 1 tablet by mouth once daily	☐ 30 Tablets	
	☐ 30 mg XR Tablet	☐ Atopic Dermatitis Dose (if inadequate response): Take 1 tablet by mouth once daily		
☐ Skyrizi®	☐ 150 mg/mL Pen ☐ 150 mg/mL Prefilled Syringe	☐ Initiation Dose: Inject 150 mg SUBQ at week 0 and 4, followed by every 12 weeks thereafter	☐ 1 Pen/PFS	0
		☐ Maintenance Dose: Inject 150 mg SUBQ at week 4, then every 12 weeks thereafter	☐ 1 Pen/PFS	
☐ Sotyktu®	☐ 6 mg Tablet	☐ Take 1 tablet by mouth once daily	☐ 30 Tablets	
☐ Stelara®	☐ 90 mg/mL Prefilled Syringe	☐ Psoriasis (> 100 kg) Initiation Dose: Inject 90 mg SUBQ at weeks 0 and 4, and then every 12 weeks thereafter	☐ 1 PFS	0
		☐ Psoriasis (> 100 kg) Maintenance Dose: Inject 90 mg SUBQ at week 4, then every 12 weeks thereafter	☐ 1 PFS	
	☐ 45 mg/0.5 mL Prefilled Syringe	☐ Psoriasis (adults ≤ 100 kg and pediatrics 60 to 100 kg) Initiation Dose: Inject 45 mg SUBQ at weeks 0 and 4, and then every 12 weeks thereafter	☐ 1 PFS	0
		☐ Psoriasis (adults ≤ 100 kg and pediatrics 60 to 100 kg) Maintenance Dose: Inject 45 mg SUBQ at week 4, then every 12 weeks thereafter	☐ 1 PFS	
	☐ 45 mg/0.5 mL Single-dose Vial	☐ Psoriasis (pediatrics < 60 kg) Initiation Dose: Inject 0.75 mg/kg (dose = _____ mg) SUBQ at weeks 0 and 4, and then every 12 weeks thereafter	☐ 1 Vial	0
		☐ Psoriasis (pediatrics < 60 kg) Maintenance Dose: Inject 0.75 mg/kg (dose = _____ mg) SUBQ at week 4, then every 12 weeks thereafter	☐ 1 Vial	

Physician signature required

Product substitution permitted	**Dispense as written**
X _____ Date _____	X _____ Date _____

Ancillary supplies and kits will be provided as needed for administration.

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document.

☐ Taltz®	☐ 80 mg/mL Pen ☐ 80 mg/mL Prefilled Syringe	☐ Psoriasis Initiation Dose: Inject 160 mg SUBQ week 0, followed by 80 mg week 2, 4, 6, 8, 10, 12 and then every 28 days thereafter	☐ 8 Pens/PFS	0
		☐ Psoriasis (pediatrics > 50 kg) Initiation Dose: Inject 160 mg SUBQ week 0, followed by 80 mg every 28 days thereafter	☐ 2 Pen/PFS	0
		☐ Psoriasis (pediatrics 25 to 50 kg) Initiation Dose: Inject 80 mg SUBQ week 0, followed by 40 mg every 28 days thereafter	☐ 1 Pen/PFS	0
		☐ Psoriasis Maintenance Dose: Inject 80 mg SUBQ every 28 days	☐ 1 Pen/PFS	
	☐ 40 mg/mL Prefilled Syringe	☐ Psoriasis (pediatrics < 25 kg) Initiation Dose: Inject 40 mg SUBQ week 0, followed by 20 mg every 28 days thereafter	☐ 1 PFS	0
		☐ Psoriasis (pediatrics 25 to 50 kg) Maintenance Dose: Inject 40 mg SUBQ every 28 days	☐ 1 PFS	
	☐ 20 mg/mL Prefilled Syringe	☐ Psoriasis (pediatrics < 25 kg) Maintenance Dose: Inject 20 mg SUBQ every 28 days	☐ 1 PFS	
☐ Tremfya®	☐ 100 mg/mL Pen ☐ 100 mg/mL Prefilled Syringe	☐ Initiation Dose: Inject 100 mg SUBQ week 0 and 4, and then every 8 weeks thereafter	☐ 1 Pen/PFS	0
		☐ Maintenance Dose: Inject 100 mg SUBQ at week 4, then every 8 weeks thereafter	☐ 1 Pen/PFS	
☐ Xolair®	☐ 150 mg/mL Prefilled Syringe ☐ 150 mg/mL Vial	☐ Inject 150 mg SUBQ once every 28 days	☐ 1 PFS/Vial	
		☐ Inject 300 mg SUBQ once every 28 days	☐ 2 PFS/Vial	

Physician signature required

Product substitution permitted	**Dispense as written**
X _____ Date _____	X _____ Date _____

Ancillary supplies and kits will be provided as needed for administration.

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document.